🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

2,153 results for “Ou” Clear

  1. NX210c, GLUCOSE 5 % B.BRAUN, solution pour perfusion

    Lacuna Pharma Pty Ltd

    Amyotrophic Lateral Sclerosis (ALS)

    phase 2 small molecule active

    1 trial

  2. NaCl 0.9%, GAMMA-OH 200 mg/ml, solution injectable (IV)

    Pari Pharma GmbH

    The study population includes adult ICU patients with a hospitalization of more than 48 hours. We have chosen to include patients with or without mechanical ventilation, as sleep disorders affect all ICU patients after 48 hours.

    phase 2 small molecule active

    1 trial

  3. Nab-paclitaxel

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Head and Neck Squamous Cell Carcinoma

    phase 2 small molecule completed

    1 trial

  4. NanoDOX Hydrogel

    United Therapeutics Europe Ltd

    Orthopedic Trauma Wounds

    phase 2 small molecule terminated

    1 trial

  5. Navigating my Journey program

    BRIGHT MINDS BIOSCIENCES INC.

    Substance-Related Disorders

    phase 2 other completed

    1 trial

  6. Neoadjuvant Chemotherapy

    Xiangya Hospital of Central South University

    High-Grade Upper Tract Urothelial Carcinoma

    phase 2 small molecule completed

    1 trial

  7. Nilotinib followed by treatment-free

    Novartis Pharmaceuticals

    Chronic Myelogenous Leukemia

    phase 2 small molecule completed

    1 trial

  8. Nimenrix powder and solvent for solution for injection in pre-filled syringe Meningococcal groups A, C, W-135 and Y conjugate vaccine, Prevenar 13 suspension for injection pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed), Rotarix oral suspension in pre-filled oral applicator Rotavirus vaccine, live, Infanrix hexa, Powder and suspension for suspension for injection. Diphtheria (D), tetanus (T), pertussis (acellular, component) (Pa), hepatitis B (rDNA) (HBV), poliomyelitis (inactivated) (IP

    GlaxoSmithKline

    Infections, Meningococcal

    phase 2 small molecule active

    1 trial

  9. Nimotuzumab

    The First People's Hospital of Lianyungang

    Esophageal Squamous Cell Carcinoma

    phase 2 small molecule active

    1 trial

  10. Nimotuzumab + SHR-1210

    The First People's Hospital of Lianyungang

    Esophageal Squamous Cell Carcinoma

    phase 2 small molecule active

    1 trial

  11. Niraparib-Bevacizumab

    Takeda

    Platinum-sensitive Recurrent Ovarian Cancer Patients Previously Treated With a PARP Inhibitor

    phase 2 small molecule active

    1 trial

  12. Nitrofurazone Group 1

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Amyotrophic Lateral Sclerosis

    phase 2 small molecule active

    1 trial

  13. Nitrous oxide

    BRIGHT MINDS BIOSCIENCES INC.

    Opioid-Related Disorders

    phase 2 small molecule completed

    1 trial

  14. Nivolumab

    Mereo BioPharma Group plc

    Ovarian Cancer

    phase 2 small molecule active

    1 trial

  15. Nivolumab Subcutaneous, BMS986482, FDC Nivolumab + Relatlimab + rHuPH20 Injection, BMS986482, BEVACIZUMAB

    Bristol-Myers Squibb Australia Pty Ltd

    Advanced Solid Tumors

    phase 2 small molecule active

    1 trial

  16. OLAPARIB, BEVACIZUMAB

    The George Institute

    Advanced FIGO Stage III‐IV High Grade Serous or Endometrioid Ovarian, Fallopian Tube, or Peritoneal Cancer

    phase 2 small molecule active

    1 trial

  17. OMP-59R5

    Mereo BioPharma Group plc

    Stage IV Pancreatic Cancer

    phase 2 small molecule completed

    1 trial

  18. OMP-59R5

    Mereo BioPharma Group plc

    Stage IV Small Cell Lung Cancer

    phase 2 small molecule terminated

    1 trial

  19. ONCOVIN 1 mg, solution injectable, CARBOPLATINE TEVA 10 mg/ml, solution pour perfusion, ENDOXAN 1000 mg, poudre pour solution injectable, ETOPOSIDE TEVA 20 mg/ml, solution à diluer pour perfusion, TEPADINA 15 mg powder for concentrate for solution for infusion, THIOTEPA GENOPHARM 15 mg, lyophilisat pour usage parentéral

    The George Institute

    Retinoblastoma

    phase 2 small molecule active

    1 trial

  20. ONO-4578, ONO-4578, BEVACIZUMAB, ONO-4578, CALCIUM FOLINATE, OXALIPLATIN, OPDIVO 10 mg/mL concentrate for solution for infusion., FLUOROURACIL

    Lacuna Pharma Pty Ltd

    PD-L1 positive advanced colorectal cancer

    phase 2 small molecule active

    1 trial

  21. OPDIVO 10 mg/mL concentrate for solution for infusion., FLUOROURACIL , Oxaliplatino Sandoz, LEDERFOLIN 175 mg polvere per soluzione per infusione, FLUOROURACIL , SIMVASTATIN, CAPECITABINE

    Fondazione Telethon ETS

    advanced or metastatic gastrooesophageal carcinoma HER2 negative and ARID1A mutated

    phase 2 small molecule active

    1 trial

  22. OPDIVO 10 mg/mL concentrate for solution for infusion., JNJ-63723283, Zr89

    Disc Medicine

    Patients with metastatic solid tumours, where clinical data has shown a rationale for ICI therapy.

    phase 2 small molecule active

    1 trial

  23. OPDIVO 10 mg/mL concentrate for solution for infusion., Kymriah 1.2 x 10^6 – 6 x 10^8 cells dispersion for infusion

    Pari Pharma GmbH

    children, adolescents and young adults with Acute Lymphoblastic Leukemia

    phase 2 small molecule active

    1 trial

  24. OPDIVO 10 mg/mL concentrate for solution for infusion., Relatlimab intravenous

    The George Institute

    Adult participants with advanced unresectable or metastatic soft-tissue sarcoma.

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources